Class
Bisphosphonate
MOA
The principal pharmacologic action of zoledronic acid is inhibition of bone resorption Although the antiresorptive mechanism is not completely understood, several factors are thought to contribute to this actionIn vitro, zoledronic acid inhibits osteoclastic activity and induces osteoclast apoptosis Zoledronic acid also blocks the osteoclastic resorption of mineralized bone and cartilage through its binding to bone It inhibits the increased osteoclastic activity and skeletal calcium release induced by various stimulatory factor sreleased by tumors.
Indications
Side Effects
Dose
Hypercalcemia of Malignancy
The maximum recommended dose of zoledronic acid is 4 mg. The 4 mg dose must be given as a single-dose intravenous infusion over no less than 15 minutes.
Retreatment with zoledronic acid 4 mg may be considered if serum calcium does not return to normal or remain normal after initial treatment. It is recommended that a minimum of 7 days elapse before retreatment, to allow for full response to the initial dose.
Multiple Myeloma and Bone Metastases of Solid Tumors
The recommended dose in patients with multiple myeloma and metastatic bone lesions from solid tumors for patients with creatinine clearance (CrCl) greater than 60 mL/min is 4 mg infused over no less than 15 minutes every 3 to 4 weeks. The optimal duration of therapy is not known.
Pack Size: 1’s
Storage (°C.): 2°-8° C
Strength: 4mg/5ml Injection
